By Counterforce Health Team in Alecensa (alectinib) —

If Alecensa (Alectinib) Isn't Approved by Aetna (CVS Health) in Texas: Formulary Alternatives & Exception Paths

Quick Answer: Your Options When Aetna Denies Alecensa

If Aetna (CVS Health) denies Alecensa (alectinib) for ALK-positive NSCLC in Texas, you have three main paths: try a formulary alternative (typically crizotinib first-line), request a formulary exception with medical necessity documentation, or appeal the denial through Texas's internal and external review process. Most denials stem from step therapy requirements or missing ALK test results. Your first step: contact CVS Caremark at 1-866-814-5506 to confirm formulary status and PA requirements for your specific plan.

Table of Contents

When Alternatives Make Sense

Before pursuing an exception or appeal, consider whether an Aetna formulary alternative might work for your situation. This approach often provides faster access to treatment while you build a case for Alecensa.

Clinical scenarios where alternatives are appropriate:

  • First-line treatment for newly diagnosed ALK-positive metastatic NSCLC
  • No prior ALK inhibitor failures
  • Absence of brain metastases requiring high CNS penetration
  • Patient can tolerate step therapy requirements

When to skip alternatives and go straight to exception:

  • Previous failure or intolerance to formulary ALK inhibitors
  • Extensive brain metastases (Alecensa has superior CNS activity)
  • Specific contraindications to preferred alternatives
  • Urgent clinical need where delays could harm outcomes
Tip: Check your specific Aetna plan's formulary using their drug search tool before making treatment decisions.

Typical Formulary Alternatives

Aetna typically covers several ALK inhibitors with varying step therapy requirements. Understanding the sequence helps you and your oncologist plan treatment strategy.

First-Line Options

Crizotinib (Xalkori)

  • Usually the preferred first-line ALK inhibitor on Aetna formularies
  • Requires ALK-positive testing but minimal step therapy
  • Lower cost than newer-generation inhibitors

Ceritinib (Zykadia)

  • May be available as first-line with specific documentation
  • Often requires prior authorization demonstrating ALK positivity
  • Higher copays than crizotinib on most plans

Second-Line After Progression

Brigatinib (Alunbrig)

  • Typically covered after crizotinib failure
  • Requires documentation of disease progression
  • Good CNS penetration for brain metastases

Lorlatinib (Lorbrena)

  • Usually reserved for multiple prior ALK inhibitor failures
  • Highest tier placement with extensive PA requirements
  • Most potent CNS activity among ALK inhibitors

Coverage at a Glance

Requirement What It Means Where to Find It
ALK Testing FDA-approved test confirming ALK rearrangement Pathology report, molecular testing lab
Step Therapy Try crizotinib before second-generation drugs Aetna formulary documents
Prior Authorization Pre-approval needed for coverage CVS Caremark portal or phone
Quantity Limits Monthly supply restrictions (typically 30-day) Plan benefits summary
Site of Care Specialty pharmacy requirement CVS Specialty coordination

Pros and Cons Overview

Formulary Alternatives Approach

Advantages:

  • Faster access to treatment (days vs. weeks)
  • Lower out-of-pocket costs on most plans
  • Established coverage pathway
  • Clinical efficacy proven in ALK-positive NSCLC

Disadvantages:

  • May not be optimal for your specific situation
  • Potential for treatment delays if alternative fails
  • Side effect profiles differ between agents
  • May need to document failure before accessing preferred drug

Exception Request Approach

Advantages:

  • Direct path to your preferred medication
  • No need to try potentially suboptimal alternatives
  • Preserves treatment timeline for urgent cases
  • Maintains physician's preferred treatment plan

Disadvantages:

  • Longer approval process (24-48 hours minimum)
  • Higher chance of initial denial
  • Requires extensive documentation
  • May trigger peer-to-peer review requirements
From our advocates: "We've seen many patients successfully get Alecensa approved on exception when their oncologist provided clear documentation of why crizotinib wasn't appropriate—often due to extensive brain metastases or prior treatment history. The key is being specific about clinical factors rather than just stating preference."

Exception Strategy

When formulary alternatives aren't clinically appropriate, Aetna's exception process can provide coverage for non-formulary drugs or override step therapy requirements.

Step-by-Step Exception Request

  1. Contact CVS Caremark at 1-866-814-5506 to initiate the exception request
  2. Gather required documentation (see checklist below)
  3. Submit via provider portal on Availity or fax to 1-855-330-1716
  4. Track timeline - Aetna responds within 24 hours for standard requests
  5. Prepare for peer-to-peer if initial request is denied
  6. Consider expedited process for urgent clinical situations

Medical Necessity Documentation Checklist

Your oncologist should include:

  • ALK-positive diagnosis with specific test results and methodology
  • Clinical rationale for Alecensa over formulary alternatives
  • Contraindications to step therapy options (if applicable)
  • Prior treatment history including failures or intolerances
  • Disease characteristics (brain metastases, performance status)
  • Treatment goals and expected outcomes
  • Monitoring plan for liver function and other safety parameters

Supporting Evidence to Include

  • FDA labeling supporting your specific indication
  • NCCN guidelines (current version 3.2025) recommending Alecensa
  • Clinical trial data showing superiority in your clinical scenario
  • Peer-reviewed literature on ALK inhibitor sequencing

Switching Logistics

If you start with a formulary alternative and need to switch to Alecensa later, proper coordination prevents treatment gaps.

Provider Coordination

  • Document response to initial therapy with imaging and clinical notes
  • Plan transition timing to minimize washout periods
  • Coordinate monitoring for overlapping toxicities
  • Update prior authorization before switching medications

Pharmacy Coordination

  • CVS Specialty handles most Aetna specialty medications
  • Transfer prescriptions between specialty pharmacies if needed
  • Verify coverage before discontinuing current therapy
  • Coordinate delivery to prevent treatment interruptions

Monitoring During Transition

  • Baseline labs before starting new therapy
  • Imaging assessment to document disease status
  • Toxicity evaluation from previous treatment
  • Drug interaction screening if switching quickly

Re-trying for Alecensa Later

If you initially receive a formulary alternative, building a strong case for future Alecensa approval requires careful documentation throughout treatment.

What to Document During Alternative Therapy

Treatment Response:

  • Serial imaging results showing progression or suboptimal response
  • Quantitative tumor measurements and progression dates
  • Biomarker changes if available (CEA, other tumor markers)

Toxicity Issues:

  • Specific adverse events with severity grades
  • Dose reductions or treatment interruptions
  • Quality of life impacts affecting daily functioning

Clinical Deterioration:

  • Performance status changes
  • New symptoms or disease complications
  • CNS progression requiring better brain penetration

Timing Your Re-appeal

Optimal timing for Alecensa request:

  • Clear radiographic progression on current therapy
  • Documented intolerance requiring dose modifications
  • Development of brain metastases needing CNS-active therapy
  • After completing required step therapy duration per policy

Counterforce Health specializes in turning these documented treatment failures into targeted, evidence-backed appeals that align with Aetna's specific coverage criteria. Their platform analyzes denial patterns and crafts point-by-point rebuttals using the right clinical evidence and procedural requirements.

Appeals Process in Texas

When exception requests fail, Texas provides robust appeal rights through both internal and external review processes.

Internal Appeals with Aetna

  • Timeline: File within 180 days of denial
  • Decision deadline: 30 days for pre-service, 60 days for post-service
  • Expedited process: Available for urgent cases (72-hour decision)
  • Contact: Submit through member portal or mail to Aetna PA, 1300 E. Campbell Rd., Richardson, TX 75081

External Review in Texas

  • When available: After internal appeal denial for medical necessity disputes
  • Timeline: File within 4 months of final internal denial
  • Decision deadline: 20 days standard, 5 days for urgent cases
  • Cost: Paid by Aetna, no charge to patient
  • Binding: Aetna must comply with favorable IRO decisions

Getting Help in Texas

  • Texas Department of Insurance: 1-800-252-3439 for general guidance
  • Office of Public Insurance Counsel: 1-877-611-6742 for appeals assistance
  • IRO Information Line: 1-866-554-4926 for external review questions
Note: ERISA self-funded employer plans follow federal appeal rules and aren't subject to Texas external review. Check your plan documents to determine which process applies.

FAQ

How long does Aetna PA take for Alecensa in Texas? Standard prior authorization decisions are made within 24-48 hours. Expedited requests for urgent cases can be decided within 24 hours. Complex cases requiring peer-to-peer review may take 3-5 business days.

What if Alecensa is completely non-formulary on my plan? You can request a formulary exception with medical necessity documentation. Aetna must cover non-formulary drugs when medically necessary and no appropriate formulary alternatives exist.

Can I request an expedited appeal for cancer treatment? Yes, both internal appeals and external reviews can be expedited when delays would jeopardize your health. Urgent cases are decided within 72 hours (internal) or 5 days (external review).

Does step therapy apply if I failed ALK inhibitors outside Texas? Prior treatment failures from other states count toward step therapy requirements. Provide documentation of previous therapies, including dates, duration, and reasons for discontinuation.

What happens if CVS Specialty can't fill my prescription? Aetna may allow exceptions to use non-CVS specialty pharmacies when CVS cannot provide the medication or service. Contact member services to request a network exception.

How much does Alecensa cost with Aetna coverage? Costs vary by plan tier and deductible status. Specialty tier copays typically range from $50-$500+ per month. Check your specific plan benefits or use Aetna's cost estimator tool.

This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider about treatment decisions and work with your insurance company to understand your specific coverage. For questions about Texas insurance regulations, contact the Texas Department of Insurance at 1-800-252-3439.

Need help with your appeal? Counterforce Health helps patients and clinicians turn insurance denials into successful appeals by analyzing payer policies and crafting evidence-backed responses that meet specific procedural requirements.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.